ReviewNeoReviews2021
Neonatal Cholestasis: Updates on Diagnostics, Therapeutics, and Prevention.
Review in NeoReviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 61 citations in OpenAlex.
- Presumptive Bilirubin-Related Chlorodontia and Developmental Enamel Defects of the Primary Dentition in an Extremely Preterm Infant: A Case Report.Journal of clinical medicine · 2026Article
- Advancing precision hepatology for rare paediatric liver diseases.European journal of pediatrics · 2026Review
- Article
- Biochemical metabolic bone disease in preterm infants: clinical determinants, markers and risk of fracture in a cohort study.BMC pediatrics · 2026Article
- Pediatric Cholestasis: A Practical Approach to Histological Diagnosis.Diagnostics (Basel, Switzerland) · 2026Review
- Potential role of NLRP3 genetic polymorphism and gene expression in differentiating causes of neonatal cholestasis.Clinical and experimental hepatology · 2026Article
- Whole-exome sequencing illuminates unexplained pediatric cholestatic liver disease.World journal of hepatology · 2026Article
- Research Progress on Mesenchymal Stem Cells-Derived Small Size Vesicles for the Treatment of Liver Diseases.International journal of nanomedicine · 2026Review
- Clinical utility of an evolving cholestasis gene panel in 10,000 children and adults.Frontiers in pediatrics · 2026Article
- Case Report: Early recognition of neonatal alpha-1 antitrypsin deficiency: a case of subtle presentation and prompt diagnosis.Frontiers in pediatrics · 2026Article
- Research progress on the role of bile acid metabolism in intestinal epithelial cell injury in necrotizing enterocolitis.Frontiers in pediatrics · 2026Review
- Does Gamma-Glutamyl Transpeptidase Serum Level Play a Role as a Prognostic Marker in Biliary Atresia, an Immune-Mediated Cholangiopathy in Children?Journal of clinical medicine · 2025Article
- Development and validation of a screening model for early diagnosis of biliary atresia in neonates with cholestasis.Pediatric surgery international · 2025Article
- Fecal microbiome profiles in infants with biliary atresia versus nonbiliary atresia cholestasis: a pilot study.Clinical and experimental pediatrics · 2025Article
- Ursodeoxycholic acid for the treatment of cholestasis in newborn infants.The Cochrane database of systematic reviews · 2025Article
- Mechanism of NOTCH2 in promoting intrahepatic bile duct development.BMC gastroenterology · 2025Article
- The Gut Microbiota Metabolite Urolithin B Mitigates Cholestatic Liver Injury in Mice via Modulating the Crosstalk Between PPARα, Nrf2, and NF-κB Signaling Pathways.Journal of xenobiotics · 2025Article
- Sequential direct bilirubin values in preterm infants.Journal of perinatology : official journal of the California Perinatal Association · 2025Article
- Review
- Pediatric hepatobiliary scintigraphy: biliary atresia and beyond.Pediatric radiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Cholestatic jaundice is a common presenting feature of hepatobiliary and/or metabolic dysfunction in the newborn and young infant. Timely detection of cholestasis, followed by rapid step-wise evaluation to determine the etiology, is crucial to identify those causes that are amenable to medical or surgical intervention and to optimize outcomes for all infants. In the past 2 decades, genetic etiologies have been elucidated for many cholestatic diseases, and next-generation sequencing, whole-exome sequencing, and whole-genome sequencing now allow for relatively rapid and cost-effective diagnosis of conditions not previously identifiable via standard blood tests and/or liver biopsy. Advances have also been made in our understanding of risk factors for parenteral nutrition-associated cholestasis/liver disease. New lipid emulsion formulations, coupled with preventive measures to decrease central line-associated bloodstream infections, have resulted in lower rates of cholestasis and liver disease in infants and children receiving long-term parental nutrition. Unfortunately, little progress has been made in determining the exact cause of biliary atresia. The median age at the time of the hepatoportoenterostomy procedure is still greater than 60 days; consequently, biliary atresia remains the primary indication for pediatric liver transplantation. Several emerging therapies may reduce the bile acid load to the liver and improve outcomes in some neonatal cholestatic disorders. The goal of this article is to review the etiologies, diagnostic algorithms, and current and future management strategies for infants with cholestasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.